Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02592707 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
A Phase 1 study, sponsored by Ipsen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02592707 is a Phase 1 study that was terminated before completion, run by Ipsen. The registered enrollment target is 40 participants.
The verdict
NCT02592707, a Phase 1 study, was terminated before completion, sponsored by Ipsen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this clinical phase I/II study was to investigate the safety and tolerability of satoreotide tetraxetan (177Lu-IPN01072, formerly known as 177Lu-OPS201) used for the treatment of patients with neuroendocrine tumors (NETs). The secondary objectives of this study were the assessment of biodistribution, dosimetry and preliminary efficacy of satoreotide tetraxetan.
Interventions
- DRUG Satoreotide tetraxetan
- OTHER Amino acid solution
- OTHER Antiemetic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-03-06 |
| Est. Completion | 2022-02-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02592707
The ClinicalTrials.gov registry entry for NCT02592707 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Satoreotide tetraxetan is the first listed.
NCT02592707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02592707 about?
NCT02592707 is a clinical study titled "Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs". The purpose of this clinical phase I/II study was to investigate the safety and tolerability of satoreotide tetraxetan (177Lu-IPN01072, formerly known as 177Lu-OPS201) used for the treatment of patients with neuroendocrine tumors (NETs). The secondary objectives of this study were the assessment of ...
What is the current status of trial NCT02592707?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2017-03-06. Estimated completion is 2022-02-22.
What interventions are being tested in trial NCT02592707?
The interventions under investigation include: Satoreotide tetraxetan (DRUG), Amino acid solution (OTHER), Antiemetic (OTHER).
Who is sponsoring clinical trial NCT02592707?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.